MRSN vs. IOBT, MOLN, IMRX, GNLX, HURA, CTOR, CLYM, ALTS, ACOG, and IKT
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include IO Biotech (IOBT), Molecular Partners (MOLN), Immuneering (IMRX), Genelux (GNLX), TuHURA Biosciences (HURA), Citius Oncology (CTOR), Climb Bio (CLYM), ALT5 Sigma (ALTS), Alpha Cognition (ACOG), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs. Its Competitors
IO Biotech (NASDAQ:IOBT) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.
Mersana Therapeutics has higher revenue and earnings than IO Biotech. IO Biotech is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
IO Biotech has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. IO Biotech's return on equity of -281.82% beat Mersana Therapeutics' return on equity.
54.8% of IO Biotech shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 2.3% of IO Biotech shares are held by company insiders. Comparatively, 13.0% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Mersana Therapeutics had 4 more articles in the media than IO Biotech. MarketBeat recorded 6 mentions for Mersana Therapeutics and 2 mentions for IO Biotech. IO Biotech's average media sentiment score of 0.97 beat Mersana Therapeutics' score of 0.17 indicating that IO Biotech is being referred to more favorably in the media.
IO Biotech has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
IO Biotech presently has a consensus target price of $8.67, suggesting a potential upside of 406.82%. Mersana Therapeutics has a consensus target price of $56.60, suggesting a potential upside of 639.87%. Given Mersana Therapeutics' higher possible upside, analysts clearly believe Mersana Therapeutics is more favorable than IO Biotech.
Summary
Mersana Therapeutics beats IO Biotech on 10 of the 16 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 8/25/2025 by MarketBeat.com Staff
MarketBeat All Access